Improvement of mitochondrial NAD+/FAD+-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: Implications in Huntington's disease

Pharmacological Reports

Volumn 66, Issue 6, 2014, Pages 1148-1155

  Mishra, Jitendriya ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Adenosine A2A receptor; Caffeine; Mitochondria; Oxidative stress

Indexed keywords

CAFFEINE; CATALASE; CYTOCHROME C OXIDASE; FLAVINE ADENINE NUCLEOTIDE; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRITE; QUINOLINIC ACID; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE DISMUTASE; UBIQUINOL CYTOCHROME C REDUCTASE; ANTIOXIDANT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; GRIP STRENGTH; HUNTINGTON CHOREA; LIPID PEROXIDATION; LOCOMOTION; LONG TERM CARE; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; RAT; WEIGHT REDUCTION; ANIMAL; CELL RESPIRATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUNTINGTON DISEASE; METABOLISM; NEUROTOXICITY SYNDROMES; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; CAFFEINE; CELL RESPIRATION; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVIN-ADENINE DINUCLEOTIDE; HUNTINGTON DISEASE; MITOCHONDRIA; NAD; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OXIDATIVE STRESS; QUINOLINIC ACID; RATS;

EID: 84908681056     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.07.006     Document Type: Article

References (56)

1. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-71.
2. Lugo-Huitron R, Muniz PU, Pineda B, Pedraza-Chaverri J, Rios C, Perez-de la Cruz V. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxidative Med Cell Longev 2013;2013:14.
3. Choi DW. Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci 1994; 747:162-71.
4. Hurley SD, Olschowka JA, O'Banion MK. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 2002;19:1-15.
5. Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996;67: 2282-91.
6. Peng TI, Greenamyre JT. Privileged access to mitochondria of calcium influx through n-methyl-D-aspartate receptors. Mol Pharmacol 1998;53:974-80.
7. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 1997;69:581-93.
8. Andreyev AY, Fahy B, Fiskum G. Cytochromec release from brain mitochondria is independent of the mitochondrial permeability transition. FEBS Lett 1998;439:373-6.
9. +: implications for neurodegeneration. J Neurochem 1994;63:584-91.
10. Rossato JI, Zeni G, Mello CF, Rubin MA, Rocha JB. Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat. Neurosci Lett 2002;318:137-40.
11. Ganzella M, Jardim FM, Boeck CR, Vendite D. Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice. Neurosci Res 2006;55:397-402.
12. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983;24:93-8.
13. Arnaud MJ. Identification, kinetic and quantitative study of [2-14C] and [1-Me-14C]caffeine metabolites in rat's urine by chromatographic separations. Biochem Med 1976;16:67-76.
14. Waldeck B. Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Acta Pharmacol Toxicol (Copenh) 1975;36:1-23.
15. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanismsofaction, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992;17:139-70.
16. Bedingfield JB, King DA, Holloway FA. Cocaine and caffeine: conditioned place preference, locomotor activity, and additivity. Pharmacol Biochem Behav 1998;61:291-6.
17. Finn IB, Holtzman SG. Tolerance to caffeine-induced stimulation of locomotor activity in rats. J Pharmacol Exp Ther 1986;238:542-6.
18. Goldstein A, Kaizer S, Warren R. Psychotropic effects of caffeine in man. II. Alertness, psychomotor coordination, and mood. J Pharmacol Exp Ther 1965; 150:146-51.
19. James JE. Does caffeine enhance or merely restore degraded psychomotor performance? Neuropsychobiology 1994;30:124-5.
20. James JE. Caffeine and psychomotor performance revisited. Neuropsychobiology 1995;31:202-3.
21. Evans SM, Pinto Pereira LM, Addae JI. Neuroprotection by caffeine and pentoxifylline during experimental cerebral ischaemia. West Indian Med J 1999;48:23-5.
22. Fernstrom JD, Fernstrom MH. Effects of caffeine on monoamine neurotransmitters in the central and peripheral nervous system. In: Dews PB, editor. Caffeine. Berlin, Heidelberg: Springer; 1984. p. 107-18.
23. Fredholm BB, Svenningsson P. Adenosine-dopamine interactions: development ofaconcept and some commentsontherapeutic possibilities. Neurology 2003;61:S5-9.
24. Cechella J, Leite M, Dobrachinski F, Rocha J, Carvalho N, Duarte MMF, et al. Moderate swimming exercise and caffeine supplementation reduce the levels of inflammatory cytokines without causing oxidative stress in tissues of middle-aged rats. Amino Acids 2014;46:1187-95.
25. Prasanthi JR, Dasari B, Marwarha G, Larson T, Chen X, Geiger JD, et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced bycholesterol-enriched diet. Free Radic Biol Med 2010;49:1212-20.
26. Dragicevic N, Delic V, Cao C, Copes N, Lin X, Mamcarz M, et al. Caffeine increases mitochondrial function and blocks melatonin signalingtomitochondria in Alzheimer's mice and cells. Neuropharmacology 2012;63:1368-79. http://dx.doi.org/10.016/j.neuropharm.2012.08.018 [Epub Sep 1].
27. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. San Diego: Academic Press; 2007.
28. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1217-40.
29. Aguiar LMV, Nobre Jr HV, Macêdo DS, Oliveira AA, Freitas RM, Vasconcelos SM, et al. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 2006;84:415-9.
30. Bishnoi M, Chopra K, Kulkarni SK. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 2006; 552:55-66.
31. Kumar A, Chaudhary T, Mishra J. Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences. Eur J Pharmacol 2013;720:16-28.
32. Kumar A, Sharma N, Mishra J, Kalonia H. Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. Eur J Pharmacol 2013;709:1-12.
33. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J 1966;99:667-76.
34. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982;126:131-8.
35. Luck H. Catalase. In: Hans UB, editor. Methods of enzymatic analysis. 2nd ed., New York: Academic Press; 1965. p. 885-94.
36. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 1978;186:189-95.
37. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
38. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949;177:751-66.
39. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999;73:1127-37.
40. King TE, Howard RL. Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods enzymol 1967;10:275-94.
41. King TE. Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods enzymol 1967;10:322-31.
42. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 1967;32:415-38.
43. Clark JB, Nicklas WJ. The metabolism of rat brain mitochondria: preparation and characterization. J Biol Chem 1970;245:4724-31.
44. Estabrook RW. Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios. Methods Enzymol 1967;10:41-7.
45. Kalonia H, Mishra J, Kumar A. Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic acid induced Huntington's disease-like symptoms in rats. Neurotox Res 2012;22:310-20.
46. Mishra J, Chaudhary T, Kumar A. Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARgamma and HDAC pathways. Neurotox Res 2014. http://dx.doi.org/10.1007/s12640-014-9458-z.
47. Hinton SC, Paulsen JS, Hoffmann RG, Reynolds NC, Zimbelman JL, Rao SM. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007;13:539-43.
48. Aldridge JW, Berridge KC, Rosen AR. Basal ganglia neural mechanisms of natural movement sequences. Can J Physiol Pharmacol 2004;82:732-9.
49. Ribeiro CA, Grando V, Dutra Filho CS, Wannmacher CM, Wajner M. Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem 2006; 99:1531-42.
50. Kalonia H, Kumar P, Kumar A. Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. Brain Res 2011;1372:115-26.
51. Vignoli JA, Bassoli DG, Benassi MT. Antioxidant activity, polyphenols, caffeine and melanoidins in soluble coffee: the influence of processing conditions and raw material. Food Chem 2011;124:863-8.
52. Chu Y-F, Chen Y, Brown PH, Lyle BJ, Black RM, Cheng IH, et al. Bioactivities of crude caffeine: antioxidant activity, cyclooxygenase-2 inhibition, and enhanced glucose uptake. Food Chem 2012;131:564-8.
53. Beal MF. Does impairmentofenergy metabolism resultinexcitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-30.
54. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41: 160-5.
55. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 1997;388:674-8.
56. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pezzola A, et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 2002;22:1967-75.